8-K
NOVANTA INC (NOVT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2023
NOVANTA INC.
(Exact name of registrant as specified in is charter)
| New Brunswick, Canada | 001-35083 | 98-0110412 |
|---|---|---|
| (State or other jurisdiction<br><br>of incorporation) | (Commission File Number) | (IRS Employer<br><br>Identification No.) |
| 125 Middlesex Turnpike<br><br>Bedford, Massachusetts | 01730 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (781) 266-5700
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common shares, no par value | NOVT | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2023, Novanta Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1.
The information contained in this Current Report, including Exhibit 99.1, is furnished under this Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing thereunder or under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit<br><br>Number | Description |
|---|---|
| 99.1 | Press Release, dated May 9, 2023 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Novanta Inc. | ||
|---|---|---|
| Date: May 9, 2023 | By: | /s/ Robert J. Buckley |
| Robert J. Buckley | ||
| Chief Financial Officer |
EX-99
Exhibit 99.1
FOR IMMEDIATE RELEASE May 9, 2023
Novanta Announces Financial Results for the First Quarter 2023
• First Quarter 2023 GAAP Revenue increased 7% to $219 million
• First Quarter 2023 GAAP Net Income of $18 million
• First Quarter 2023 GAAP Diluted Earnings Per Share of $0.51
• First Quarter 2023 Adjusted Earnings Per Share of $0.74
• First Quarter 2023 Adjusted EBITDA of $47 million
BEDFORD, Mass., May 9, 2023 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2023.
| Financial Highlights | Three Months Ended | |||
|---|---|---|---|---|
| (In millions, except per share amounts) | March 31, | April 1, | ||
| 2023 | 2022 | |||
| GAAP | ||||
| Revenue | $ | 219.1 | $ | 204.2 |
| Operating Income | $ | 26.3 | $ | 24.3 |
| Consolidated Net Income | $ | 18.3 | $ | 18.8 |
| Diluted EPS | $ | 0.51 | $ | 0.53 |
| Non-GAAP* | ||||
| Adjusted Operating Income | $ | 36.9 | $ | 33.5 |
| Adjusted Diluted EPS | $ | 0.74 | $ | 0.73 |
| Adjusted EBITDA | $ | 47.0 | $ | 43.6 |
*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below.
“Our first quarter results are a solid start to the year, thanks to the strong growth we are seeing in our medical end-markets,” said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. “Our teams continue to execute well, reducing past-due orders to customers, while also maintaining overall customer backlog levels, resulting in strong organic growth, gross margins, and profit growth in the quarter.”
First Quarter
During the first quarter of 2023, Novanta generated GAAP revenue of $219.1 million, an increase of $14.9 million, or 7.3%, versus the first quarter of 2022. The Company’s acquisition activities resulted in an increase in revenue of $3.5 million, or 1.7%, compared to the first quarter of 2022. Changes in foreign currency exchange rates year over year adversely impacted our revenue by $5.8 million, or 2.8%, during the first quarter of 2023. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 8.4% for the first quarter of 2023 (see “Organic Revenue Growth” in the non-GAAP reconciliations below).
In the first quarter of 2023, GAAP operating income was $26.3 million, compared to $24.3 million in the first quarter of 2022. GAAP net income was $18.3 million in the first quarter of 2023, compared to $18.8 million in the first quarter of
- GAAP diluted earnings per share (“EPS”) was $0.51 in the first quarter of 2023, compared to $0.53 in the first quarter of 2022.
Adjusted Diluted EPS was $0.74 in the first quarter of 2023, compared to $0.73 in the first quarter of 2022. The Company ended the first quarter of 2023 with 36.0 million diluted weighted average shares outstanding. Adjusted EBITDA was $47.0 million in the first quarter of 2023, compared to $43.6 million in the first quarter of 2022.
Operating cash flow for the first quarter of 2023 was $10.2 million, compared to $11.3 million for the first quarter of 2022. The Company completed the first quarter of 2023 with approximately $423.4 million of total debt and $82.7 million of total cash. Net Debt, as defined in the non-GAAP reconciliation below, was $345.3 million.
During the first quarter of 2023, the Company changed the names of its reportable segments from "Photonics" to "Precision Medicine and Manufacturing", from "Vision" to "Medical Solutions", and from "Precision Motion" to "Robotics and Automation", respectively. The segment name changes did not result in any change to the compositions of the segments and therefore did not result in any change to historical results. The Company changed the names of these segments to better reflect the strategic focus of their technologies and applications.
Financial Guidance
“Strong growth in our medical end-markets drove our excellent first quarter financial performance,” said Matthijs Glastra. “We are on track with our previously issued full year 2023 guidance, and expect to drive a more linear first half financial performance. In addition, demand continues to build beyond 2023 from the new products launching in our medical and industrial applications, which are on track to launch later in 2023 and in 2024.”
For the second quarter of 2023, the Company expects GAAP revenue of approximately $222 million to $225 million. The Company expects Adjusted EBITDA to be in the range of $47 million to $49 million and Adjusted Diluted EPS to be in the range of $0.70 to $0.74. The Company’s guidance assumes no significant changes in foreign exchange rates.
Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted Diluted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including future changes in the fair value of contingent considerations; significant discrete income tax expenses (benefits); divestitures and related expenses; acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; future restructuring expenses; foreign exchange gains/(losses); benefits or expenses associated with the completion of tax audits; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non-GAAP Financial Measures” below.
Conference Call Information
The Company will host a conference call on Tuesday, May 9, 2023 at 10:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Monday, July 3, 2023.
Use of Non-GAAP Financial Measures
The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income and Operating Margin, Adjusted Income before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Net Income, and Net Debt.
The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisition of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.
The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margins are used to determine bonus payments for senior management and employees. The Company also uses Adjusted Diluted EPS and Adjusted EBITDA as performance targets for certain performance-based restricted stock units issued to certain executives. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.
Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.
Safe Harbor and Forward-Looking Information
Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the second quarter of 2023; expectations for our end markets and market position; expectations regarding our ability to navigate difficult macroeconomic conditions; our ability to deliver sustained long-term shareholder value; expectations regarding our backlog and demand in our medical and advanced industrial end-markets; and other statements that are not historical facts.
These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with epidemics or pandemics, such as the COVID-19
pandemic and other events outside our control; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate, introduce new products timely, and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors may cause fluctuations in our operating results; cyberattacks, disruptions or other breaches in security of our and our third-party providers’ information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with cour operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; the continuing impact of “Brexit”; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components or other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to excess inventories or delays in the delivery of our products; production difficulties and product delivery delays or disruptions; our exposure to medical device regulations, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; potential penalties for violating foreign, U.S. federal, and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations affecting our business or products; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social and Governance policies and practices; our reliance on original equipment manufacturer customers; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws, and fluctuations in our effective tax rates; our exposure to the credit risk of some of our customers and in weakened markets; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.
Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.
About Novanta
Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”
More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com.
Novanta Inc.
Investor Relations Contact:
Ray Nash
(781) 266-5137
NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars or shares, except per share amounts)
(Unaudited)
| Three Months Ended | ||||||
|---|---|---|---|---|---|---|
| March 31, | April 1, | |||||
| 2023 | 2022 | |||||
| Revenue | $ | 219,126 | $ | 204,216 | ||
| Cost of revenue | 121,498 | 113,940 | ||||
| Gross profit | 97,628 | 90,276 | ||||
| Operating expenses: | ||||||
| Research and development and engineering | 22,828 | 20,929 | ||||
| Selling, general and administrative | 40,923 | 39,352 | ||||
| Amortization of purchased intangible assets | 5,089 | 7,342 | ||||
| Restructuring, acquisition, and related costs | 2,476 | (1,630 | ) | |||
| Total operating expenses | 71,316 | 65,993 | ||||
| Operating income | 26,312 | 24,283 | ||||
| Interest income (expense), net | (6,332 | ) | (3,109 | ) | ||
| Foreign exchange transaction gains (losses), net | (77 | ) | 69 | |||
| Other income (expense), net | (166 | ) | (545 | ) | ||
| Income before income taxes | 19,737 | 20,698 | ||||
| Income tax provision (benefit) | 1,472 | 1,878 | ||||
| Consolidated net income | $ | 18,265 | $ | 18,820 | ||
| Earnings per common share: | ||||||
| Basic | $ | 0.51 | $ | 0.53 | ||
| Diluted | $ | 0.51 | $ | 0.53 | ||
| Weighted average common shares outstanding—basic | 35,810 | 35,538 | ||||
| Weighted average common shares outstanding—diluted | 35,999 | 35,781 |
NOVANTA INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars)
(Unaudited)
| March 31, | December 31, | |||
|---|---|---|---|---|
| 2023 | 2022 | |||
| ASSETS | ||||
| Current Assets | ||||
| Cash and cash equivalents | $ | 82,676 | $ | 100,105 |
| Accounts receivable, net | 141,472 | 137,697 | ||
| Inventories | 166,671 | 167,997 | ||
| Prepaid expenses and other current assets | 13,974 | 14,720 | ||
| Total current assets | 404,793 | 420,519 | ||
| Property, plant and equipment, net | 103,967 | 103,186 | ||
| Operating lease assets | 41,964 | 43,317 | ||
| Intangible assets, net | 168,828 | 175,766 | ||
| Goodwill | 482,520 | 478,897 | ||
| Other assets | 23,743 | 19,527 | ||
| Total assets | $ | 1,225,815 | $ | 1,241,212 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current Liabilities | ||||
| Current portion of long-term debt | $ | 4,904 | $ | 4,800 |
| Accounts payable | 66,009 | 75,225 | ||
| Accrued expenses and other current liabilities | 71,440 | 84,497 | ||
| Total current liabilities | 142,353 | 164,522 | ||
| Long-term debt | 418,535 | 430,662 | ||
| Operating lease liabilities | 39,578 | 40,808 | ||
| Other long-term liabilities | 27,332 | 27,634 | ||
| Total liabilities | 627,798 | 663,626 | ||
| Stockholders’ Equity: | ||||
| Total stockholders’ equity | 598,017 | 577,586 | ||
| Total liabilities and stockholders’ equity | $ | 1,225,815 | $ | 1,241,212 |
NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of U.S. dollars)
(Unaudited)
| Three Months Ended | ||||||
|---|---|---|---|---|---|---|
| March 31, | April 1, | |||||
| 2023 | 2022 | |||||
| Cash flows from operating activities: | ||||||
| Consolidated net income | $ | 18,265 | $ | 18,820 | ||
| Adjustments to reconcile consolidated net income to<br><br>net cash provided by operating activities: | ||||||
| Depreciation and amortization | 11,731 | 14,044 | ||||
| Share-based compensation | 6,466 | 6,774 | ||||
| Deferred income taxes | (3,695 | ) | (5,140 | ) | ||
| Other | 2,587 | (1,014 | ) | |||
| Changes in assets and liabilities which (used)/provided cash,<br><br>excluding effects from business acquisitions: | ||||||
| Accounts receivable | (2,920 | ) | (8,949 | ) | ||
| Inventories | 52 | (14,928 | ) | |||
| Other operating assets and liabilities | (22,241 | ) | 1,740 | |||
| Net cash provided by (used in) operating activities | 10,245 | 11,347 | ||||
| Cash flows from investing activities: | ||||||
| Purchases of property, plant and equipment | (3,620 | ) | (6,308 | ) | ||
| Payment of contingent consideration related to acquisition of technology assets | — | (1,470 | ) | |||
| Other investing activities | — | 957 | ||||
| Net cash provided by (used in) investing activities | (3,620 | ) | (6,821 | ) | ||
| Cash flows from financing activities: | ||||||
| Repayments under term loan and revolving credit facilities | (15,309 | ) | (11,640 | ) | ||
| Payments of debt issuance costs | — | (2,133 | ) | |||
| Payments of withholding taxes from share-based awards | (9,601 | ) | (7,733 | ) | ||
| Other financing activities | (156 | ) | (523 | ) | ||
| Net cash provided by (used in) financing activities | (25,066 | ) | (22,029 | ) | ||
| Effect of exchange rates on cash and cash equivalents | 1,012 | (1,085 | ) | |||
| Increase (decrease) in cash and cash equivalents | (17,429 | ) | (18,588 | ) | ||
| Cash and cash equivalents, beginning of period | 100,105 | 117,393 | ||||
| Cash and cash equivalents, end of period | $ | 82,676 | $ | 98,805 |
NOVANTA INC.
Revenue by Reportable Segment
(In thousands of U.S. dollars)
(Unaudited)
| Three Months Ended | ||||
|---|---|---|---|---|
| March 31, | April 1, | |||
| 2023 | 2022 | |||
| Revenue | ||||
| Precision Medicine and Manufacturing | $ | 69,528 | $ | 62,782 |
| Medical Solutions | 77,640 | 62,050 | ||
| Robotics and Automation | 71,958 | 79,384 | ||
| Total | $ | 219,126 | $ | 204,216 |
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands of U.S. dollars)
(Unaudited)
Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP):
| Three Months Ended | ||||||
|---|---|---|---|---|---|---|
| March 31, | April 1, | |||||
| 2023 | 2022 | |||||
| Precision Medicine and Manufacturing | ||||||
| Gross Profit (GAAP) | $ | 34,333 | $ | 28,387 | ||
| Gross Profit Margin (GAAP) | 49.4 | % | 45.2 | % | ||
| Amortization of intangible assets | 570 | 664 | ||||
| Acquisition fair value adjustments | — | — | ||||
| Adjusted Gross Profit (Non-GAAP) | $ | 34,903 | $ | 29,051 | ||
| Adjusted Gross Profit Margin (Non-GAAP) | 50.2 | % | 46.3 | % | ||
| Medical Solutions | ||||||
| Gross Profit (GAAP) | $ | 31,886 | $ | 25,230 | ||
| Gross Profit Margin (GAAP) | 41.1 | % | 40.7 | % | ||
| Amortization of intangible assets | 1,064 | 1,257 | ||||
| Acquisition fair value adjustments | — | — | ||||
| Adjusted Gross Profit (Non-GAAP) | $ | 32,950 | $ | 26,487 | ||
| Adjusted Gross Profit Margin (Non-GAAP) | 42.4 | % | 42.7 | % | ||
| Robotics and Automation | ||||||
| Gross Profit (GAAP) | $ | 32,815 | $ | 38,150 | ||
| Gross Profit Margin (GAAP) | 45.6 | % | 48.1 | % | ||
| Amortization of intangible assets | 1,388 | 1,502 | ||||
| Acquisition fair value adjustments | — | — | ||||
| Adjusted Gross Profit (Non-GAAP) | $ | 34,203 | $ | 39,652 | ||
| Adjusted Gross Profit Margin (Non-GAAP) | 47.5 | % | 49.9 | % | ||
| Unallocated Corporate and Shared Services | ||||||
| Gross Profit (GAAP) | $ | (1,406 | ) | $ | (1,491 | ) |
| Amortization of intangible assets | — | — | ||||
| Employee COVID-19 testing costs | — | 125 | ||||
| Adjusted Gross Profit (Non-GAAP) | $ | (1,406 | ) | $ | (1,366 | ) |
| Novanta Inc. | ||||||
| Gross Profit (GAAP) | $ | 97,628 | $ | 90,276 | ||
| Gross Profit Margin (GAAP) | 44.6 | % | 44.2 | % | ||
| Amortization of intangible assets | 3,022 | 3,423 | ||||
| Acquisition fair value adjustments | — | — | ||||
| Employee COVID-19 testing costs | — | 125 | ||||
| Adjusted Gross Profit (Non-GAAP) | $ | 100,650 | $ | 93,824 | ||
| Adjusted Gross Profit Margin (Non-GAAP) | 45.9 | % | 45.9 | % |
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Amounts in thousands except per share amounts)
(Unaudited)
Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):
| Three Months Ended March 31, 2023 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | Operating Margin | Income Before Income Taxes | Income Tax Provision / (Benefit) | Effective Tax Rate | Consolidated Net Income | Diluted EPS | |||||||||||
| GAAP results | $ | 26,312 | 12.0 | % | $ | 19,737 | $ | 1,472 | 7.5 | % | $ | 18,265 | $ | 0.51 | |||
| Non-GAAP Adjustments: | |||||||||||||||||
| Amortization of intangible assets | 8,111 | 3.7 | % | 8,111 | |||||||||||||
| Restructuring costs | 2,471 | 1.1 | % | 2,471 | |||||||||||||
| Acquisition and related costs | 5 | 0.0 | % | 5 | |||||||||||||
| Foreign exchange transaction (gains) losses, net | 77 | ||||||||||||||||
| Tax effect on non-GAAP adjustments | 2,130 | ||||||||||||||||
| Non-GAAP tax adjustments | (3 | ) | |||||||||||||||
| Total non-GAAP adjustments | 10,587 | 4.8 | % | 10,664 | 2,127 | 8,537 | 0.23 | ||||||||||
| Adjusted results (Non-GAAP) | $ | 36,899 | 16.8 | % | $ | 30,401 | $ | 3,599 | 11.8 | % | $ | 26,802 | $ | 0.74 | |||
| Weighted average shares outstanding - Diluted | 35,999 |
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Amounts in thousands except per share amounts)
(Unaudited)
Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):
| Three Months Ended April 1, 2022 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | Operating Margin | Income Before Income Taxes | Income Tax Provision / (Benefit) | Effective Tax Rate | Consolidated Net Income | Diluted EPS | ||||||||||||
| GAAP results | $ | 24,283 | 11.9 | % | $ | 20,698 | $ | 1,878 | 9.1 | % | $ | 18,820 | $ | 0.53 | ||||
| Non-GAAP Adjustments: | ||||||||||||||||||
| Amortization of intangible assets | 10,765 | 5.2 | % | 10,765 | ||||||||||||||
| Restructuring costs | 622 | 0.3 | % | 622 | ||||||||||||||
| Acquisition and related costs | (2,252 | ) | (1.1 | )% | (2,252 | ) | ||||||||||||
| Employee COVID-19 testing costs | 125 | 0.1 | % | 125 | ||||||||||||||
| Write-off of unamortized deferred financing costs | 624 | |||||||||||||||||
| Foreign exchange transaction (gains) losses, net | (69 | ) | ||||||||||||||||
| Tax effect on non-GAAP adjustments | 2,232 | |||||||||||||||||
| Non-GAAP tax adjustments | 126 | |||||||||||||||||
| Total non-GAAP adjustments | 9,260 | 4.5 | % | 9,815 | 2,358 | 7,457 | 0.20 | |||||||||||
| Adjusted results (Non-GAAP) | $ | 33,543 | 16.4 | % | $ | 30,513 | $ | 4,236 | 13.9 | % | $ | 26,277 | $ | 0.73 | ||||
| Weighted average shares outstanding - Diluted | 35,781 |
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands of U.S. dollars)
(Unaudited)
Adjusted EBITDA (Non-GAAP):
| Three Months Ended | ||||||
|---|---|---|---|---|---|---|
| March 31, | April 1, | |||||
| 2023 | 2022 | |||||
| Consolidated Net Income (GAAP) | $ | 18,265 | $ | 18,820 | ||
| Consolidated Net Income Margin | 8.3 | % | 9.2 | % | ||
| Interest (income) expense, net | 6,332 | 3,109 | ||||
| Income tax provision (benefit) | 1,472 | 1,878 | ||||
| Depreciation and amortization | 11,731 | 14,036 | ||||
| Share-based compensation | 6,466 | 6,774 | ||||
| Restructuring, acquisition, and related costs | 2,476 | (1,630 | ) | |||
| Employee COVID-19 testing costs | — | 125 | ||||
| Write-off of unamortized deferred financing costs | — | 624 | ||||
| Other, net | 243 | (148 | ) | |||
| Adjusted EBITDA (Non-GAAP) | $ | 46,985 | $ | 43,588 | ||
| Adjusted EBITDA Margin (Non-GAAP) | 21.4 | % | 21.3 | % |
Organic Revenue Growth (Non-GAAP):
| Three Months Ended March 31, 2023 | |||
|---|---|---|---|
| Compared to | |||
| Three Months Ended April 1, 2022 | |||
| Reported Revenue Growth/(Decline) (GAAP) | 7.3 | % | |
| Less: Change attributable to acquisitions | 1.7 | % | |
| Plus: Change due to foreign currency | 2.8 | % | |
| Organic Revenue Growth/(Decline) (Non-GAAP) | 8.4 | % |
Net Debt (Non-GAAP):
| March 31, | December 31, | |||||
|---|---|---|---|---|---|---|
| 2023 | 2022 | |||||
| Total Debt (GAAP) | $ | 423,439 | $ | 435,462 | ||
| Plus: Deferred financing costs | 4,552 | 4,843 | ||||
| Gross Debt | 427,991 | 440,305 | ||||
| Less: Cash and cash equivalents | (82,676 | ) | (100,105 | ) | ||
| Net Debt (Non-GAAP) | $ | 345,315 | $ | 340,200 |
Free Cash Flow (Non-GAAP):
| Three Months Ended | ||||||
|---|---|---|---|---|---|---|
| March 31, | April 1, | |||||
| 2023 | 2022 | |||||
| Net Cash Provided by Operating Activities (GAAP) | $ | 10,245 | $ | 11,347 | ||
| Less: Purchases of property, plant and equipment | (3,620 | ) | (6,308 | ) | ||
| Plus: Proceeds from sale of property, plant and equipment | — | 137 | ||||
| Free Cash Flow (Non-GAAP) | $ | 6,625 | $ | 5,176 | ||
| Consolidated Net Income (GAAP) | $ | 18,265 | $ | 18,820 | ||
| Net Cash Provided by Operating Activities as a Percentage of Consolidated Net Income | 56.1 | % | 60.3 | % | ||
| Free Cash Flow as a Percentage of Consolidated Net Income | 36.3 | % | 27.5 | % |
Non-GAAP Financial Measures
Organic Revenue Growth
The Company defines the term “organic revenue” as revenue excluding the impact from business acquisitions, divestitures, product line discontinuations, and the effect of foreign currency translation. The Company uses the related term “organic revenue growth” to refer to the financial performance metric of comparing current period organic revenue with the reported revenue of the corresponding period in the prior year. The Company believes that this non-GAAP financial measure, when taken together with our GAAP financial measures, allows the Company and its investors to better measure the Company’s performance and evaluate long-term performance trends. Organic revenue growth also facilitates easier comparisons of the Company’s performance with prior and future periods and relative comparisons to its peers. The Company excludes the effect of foreign currency translation from these measures because foreign currency translation is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because these activities can vary dramatically between reporting periods and between the Company and its peers, which the Company believes makes comparisons of long-term performance trends difficult for management and investors. Organic Revenue Growth is also used as a performance metric to determine bonus payments for senior management and employees.
Adjusted Gross Profit and Adjusted Gross Profit Margin
The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin is displayed in the tables above. Adjusted Gross Profit and Adjusted Gross Profit Margin exclude amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions because: (1) the amounts are non-cash; (2) the Company cannot influence the timing and amount of future expense recognition; and (3) excluding such expenses provides investors and management better visibility into the underlying trends and performance of our businesses. Additionally, the Company excluded costs directly related to employee COVID-19 testing as these costs are unique to the COVID-19 pandemic and have had a significant impact on the Company’s operating results.
Adjusted Operating Income and Adjusted Operating Margin
The calculation of Adjusted Operating Income and Adjusted Operating Margin is displayed in the tables above. Adjusted Operating Income and Adjusted Operating Margin exclude amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, and costs directly related to employee COVID-19 testing for the reasons described for Adjusted Gross Profit and Adjusted Gross Profit Margin above. The Company also excludes restructuring and acquisition-related costs due to the significant changes that have occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”
Adjusted Income Before Income Taxes
The calculation of Adjusted Income Before Income Taxes is displayed in the tables above. The calculation of Adjusted Income Before Income Taxes excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, and restructuring and acquisition-related costs for the reasons described for Adjusted Operating Income and Adjusted Operating Margin above. The Company excludes write-off of unamortized deferred financing costs because they only arise in certain specific situations when the Company’s existing credit agreement is terminated or modified. The Company also excludes foreign exchange transaction gains (losses) from the calculation of Adjusted Income Before Income Taxes as the Company cannot fully influence the timing and amount of foreign exchange transaction gains (losses).
Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate
The Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated based on the Adjusted Income Before Income Taxes by jurisdiction and the applicable tax rates currently in effect for the respective jurisdictions. In addition, the Company excludes significant discrete income tax expenses (benefits) related to releases of valuation
allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments discussed above.
Adjusted Net Income
The calculation of Adjusted Net Income is displayed in the tables above. Because income before income taxes is included in determining Net Income, the calculation of Adjusted Net Income also excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, restructuring costs, acquisition-related costs, write-off of unamortized deferred financing costs, and foreign exchange transaction gains (losses) for the reasons described for Adjusted Income Before Income Taxes. In addition, the Company excludes significant discrete income tax expenses (benefits) related to releases of valuation allowances, expenses (benefits) associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments discussed above.
Adjusted Diluted EPS
The calculation of Adjusted Diluted EPS is displayed in the tables above. Because Net Income is used in the calculation of diluted EPS, Adjusted Diluted EPS excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, restructuring costs, acquisition-related costs, write-off of unamortized deferred financing costs, foreign exchange transaction gains (losses), significant discrete income tax expenses (benefits) related to releases of valuation allowances, expenses (benefits) associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments for the reasons described above for Adjusted Net Income.
Adjusted EBITDA and Adjusted EBITDA Margin
The Company defines Adjusted EBITDA as income before deducting interest (income) expense, income tax provision (benefit), depreciation, amortization, non-cash share-based compensation, costs directly related to employee COVID-19 testing, restructuring costs, acquisition-related costs, acquisition fair value adjustments, other non-operating (income) expense items, including foreign exchange transaction (gains) losses, write-off of unamortized deferred financing costs, and net periodic pension costs of the Company’s frozen U.K. defined benefit pension plan for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”
Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue.
In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware that in the future the Company may incur expenses that are the same as, or similar to, some of the adjustments in this presentation.
Free Cash Flow and Free Cash Flow as a Percentage of Net Income
The Company defines Free Cash Flow as net cash provided by operating activities less cash paid for purchases of property, plant and equipment and plus cash proceeds from sales of property, plant and equipment. Free Cash Flow as a Percentage of Net Income is defined as Free Cash Flow divided by Net Income. Management believes these non-GAAP financial measures are important indicators of the Company’s liquidity as well as its ability to service its outstanding debt and to fund future growth.
Net Debt
The Company defines Net Debt as its total debt as reported on the consolidated balance sheet plus unamortized deferred financing costs and less its cash and cash equivalents as of the end of the period presented. Management uses Net Debt to monitor the Company’s outstanding debt obligations that could not be satisfied by its cash and cash equivalents on hand.
* * * *